Category IMMUNOTHERAPY

PIER MARIA FORNASARI
2026-02-18

Researchers Develop New Method for Generating up to 14 milions Natural Killer Cells to Fight Cancer from a single CD34+ HSPC.

Chinese researchers have developed a novel method to efficiently engineer natural killer (NK) cells for cancer immunotherapy. NK cells are central to early antiviral and anticancer defense—among other immune system roles—making them well-suited for cancer immunotherapy. For example, chimeric antigen receptor (CAR)-NK therapy involves adding a lab-built receptor (a CAR) to an NK cell, enabling

Read More

No Comments InCANCER CAR-T IMMUNOTHERAPY
PIER MARIA FORNASARI
2025-02-26

Personalized mRNA vaccine added to standard treatment could offer new hope for pancreatic cancer patients

Adding a personalised mRNA vaccine to plain remedy might supply new hope for pancreatic cancer sufferers, a small but promising study from Memorial Sloan Kettering Cancer Center. The study adopted 16 sufferers, together with Barbara Brigham, who joined the trial after a routine scan found her early-stage pancreatic cancer. Alongside surgical procedure and chemotherapy, sufferers

Read More

No Comments InCANCER IMMUNOTHERAPY
PIER MARIA FORNASARI
2024-05-25

Combination therapy significantly improves outcomes for patients with metastatic colorectal cancer

Combining immune-targeted therapy with chemotherapy improves both progression-free survival and overall survival when compared to those who received regorafenib alone A study(Link is external) (Link opens in new window) led by UCLA Health Jonsson Comprehensive Cancer Center(Link opens in new window) researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival

Read More

No Comments InCANCER IMMUNOTHERAPY
PIER MARIA FORNASARI
2024-04-24

FDA approves immunotherapy drug combo for non-muscle invasive bladder cancer after UCLA-led research shows improved outcomes for patients

Approval is based on findings from the QUILT 3.032 clinical trial, which was led by UCLA’s Dr. Karim Chamie The U.S. Food and Drug Administration (FDA) has approved the immunotherapy-boosting drug N-803, which is marketed under the brand name Anktiva, to be used in combination with the immunotherapy Bacillus Calmette-Guerin (BCG) for the treatment of

Read More

No Comments InCANCER IMMUNOTHERAPY
PIER MARIA FORNASARI
2021-10-10

CRISPR CAR-T cells can Revolutionize Cancer Treatment

Cancer is the second leading cause of death in the United States, taking half a million lives each year. CAR T technology has successfully harnessed the human immune system to produce awe-inspiring cancer remission rates. CRISPR-mediated genome engineering has enabled new developments in CAR T cells to bypass logistical, technical, and immunological roadblocks, making the

Read More

No Comments InCANCER IMMUNOTHERAPY
PIER MARIA FORNASARI
2021-06-01

A Novel Form of Macrophage-based Immunotherapy Developed by Georgia State University Has the Potential to Revolutionize Cancer Treatment

A novel form of macrophage-based immunotherapy is effective at treating a broad spectrum of cancers, including those at advanced stages, according to a groundbreaking study led by Georgia State immunology professor Yuan Liu.  Liu’s treatment works by leveraging macrophages, specialized white blood cells involved in the detection and elimination of cancer cells and other pathogens. Macrophages also activate

Read More

No Comments InIMMUNOTHERAPY
PIER MARIA FORNASARI
2020-02-23

Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes

Immunotherapy has unleashed a revolution in care for some cancer patients. But most immunotherapies help only a small subset of patients, meaning doctors often have to resort to a trial-and-error process to determine who might actually benefit from the novel treatments. Now, scientists have developed a new metric they believe can help predict whether patients will respond

Read More

No Comments InIMMUNOTHERAPY
PIER MARIA FORNASARI
2020-02-18

Nivolumab Extends Survival in Pretreated Advanced Stomach Cancer Patients, Phase 3 Trial Results Show

The immune checkpoint inhibitor nivolumab may be a safe and effective treatment for people with advanced gastric or esophagogastric junction cancer who failed standard chemotherapy regimens, results from a Phase 3 clinical trial suggest. A three-year survival analysis of the trial, called ATTRACTION-2 (NCT02267343), showed that the treatment significantly extended patients’ lives and the time they

Read More

No Comments InIMMUNOTHERAPY
PIER MARIA FORNASARI
2020-01-08

Melanoma Immunotherapy Enhanced by Targeting Treg Cell Control Protein

Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a new potential strategy for boosting the immune system’s ability to fight cancer.  Studies in gene knockout mice, carried out in collaboration with a team at NYU Langone’s Perlmutter Cancer Center, suggested that a protein known as Siah2 is involved in the control of T

Read More

No Comments InCANCER IMMUNOTHERAPY